National Breast and Thyroid Screening After a Treatment Received Against a Cancer During Childhood

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-09

Study Completion Date

2019-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The DENACAPST programme represents an important initiative to provide near nation-wide roll-out of an important cancer surveillance program for childhood cancer survivors. The program is based on internationally recognized standards in cancer surveillance, which were developed by the International Guideline Harmonization Group (IGHG) with support of all relevant stakeholders in cancer survivorship research and clinical work in Europe, Canada and the United States and recognized French recommendations about breast screening for women at high risk of cancer.

With this programme, French centers organized themselves to provide to childhood cancer survivors adequate medical attention, which includes close medical surveillance for breast/thyroid cancer where appropriate, based on adequate risk stratification.

The aim of the study is to analyze if the recommendations about breast and thyroid cancer screening are followed in this population and secondly to provide more informations about these second cancers and about the screening.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Test of Digital Breast Tomosynthesis vs. Common Mammography to Detect Breast Cancer for Women Undergoing Breast Biopsy

NCT00535184

Breast Cancer

COMPLETED

Feasibility of Breast Cancer Risk Evaluation in Women From the General Population

NCT02997384

Breastcancer

UNKNOWN

Use of an Ultra-rapid BRCA1/2 Status Screening Test in Diagnostic and Theranostic Indication: Performance and Interest for Patients and Practitioners

NCT06111417

Breast Cancer

RECRUITING

Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)

NCT06225505

Triple Negative Breast Cancer

RECRUITING NA

Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software

NCT04980989

Breast Cancer, Early-Onset

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Every center which has patient at risk can participate. Main inclusion criteria : French childhood cancer survivor (5 years or more of delay with the treatment) - becoming adult - with a past history of radiotherapy at the age of 20 years or before, with a significant dose irradiation on the thyroid or the breast

The inclusion of patients are validated by one team

Thyroid screening programme is based on US each 2 years Breast screening programme is based mainly on MRI each year

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Early Detection of Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* childhood cancer survivor, and
* treated with radiotherapy
* health status compatible, and
* have had a long-term follow-up consultation describing a personalized post-cancer plan and,
* informed consent signed by patient

* being a woman and being 25 years or more for breast cancer screening, with a minimum delay of 8 years after radiotherapy, or
* with a significant irradiation dose to the breast (Irradiation that delivered at least 10 Gy on at least part of the breast (v 5\> 10 Gy) or on the mammary bud (v 100\> 10 Gy) - (centrally validated dose) or received TBI (Total Body Irradiation)\> 8 Gy according to a bi-fractioned scheme or\> 6 Gy in single dose)

* being a man or a woman and being 18 years or more for thyroid cancer screening with a minimum delay of 5 years after radiotherapy, and,
* with a significant irradiation dose to the thyroid (Irradiation having delivered at least 3 Gy on the thyroid (v100\> 3 Gy), or having received a TBI (Total Body Irradiation)\> 2 Gy, and / or treatment with 131i-metaiodobenzylguanidine), and

Exclusion Criteria

* life expectancy \<10 years due to other pathology
* patient in regular follow-up within the framework of a genetic susceptibility (ex li fraumeni)
* person placed under safeguard of justice

* patient treated with bilateral mastectomy, or
* patient being treated for breast cancer, or
* patient initially treated with radiotherapy for breast cancer

* Thyroidectomy, or
* patient undergoing treatment or with a personal history of thyroid cancer

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No